U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C5H10ClN3O3
Molecular Weight 195.604
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ELMUSTINE

SMILES

OCCNC(=O)N(CCCl)N=O

InChI

InChIKey=YJZJEQBSODVMTH-UHFFFAOYSA-N
InChI=1S/C5H10ClN3O3/c6-1-3-9(8-12)5(11)7-2-4-10/h10H,1-4H2,(H,7,11)

HIDE SMILES / InChI

Description

Elmustine (1-(2-hydroxyethyl)3-(2-chloroethyl)-3-nitrosourea or HECNU) is an alkylating agent with antineoplastic properties. Elmustine is monofunctional and bifunctional alkylating agent that form, in a quantitatively minor reaction, DNA-DNA crosslinks. In vitro, by far the most abundant alkylation products of DNA are those resulting from 2-hydroxyethylation. Elmustine is especially highly active against intracerebrally implanted tumors. It was in Phase II clinical trials for the treatment of glioma. Elmustine development has been discontinued.

Originator

Approval Year

PubMed

Sample Use Guides

In Vivo Use Guide
Phase II study: forty adults with recurring brain gliomas were treated with elmustine 130 mg/m2, given i.v. every 5 to 6 weeks (mean 5.4) and corticosteroids
Route of Administration: Other